TRASTUZUMAB
HER2-positive Solid Tumor
Washington University School of Medicinemonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the HER2-positive Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CINREBAFUSP ALFA Pieris Pharmaceuticals, Inc. | Phase 1 | CCC |
Atezolizumab Pieris Pharmaceuticals, Inc. | Phase 1 | CC |
Same molecule, other indications
TRASTUZUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →